Work

microRNA (miRNA) expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy (CP) in metastatic melanoma (MM) treated on the intergroup trial E2603.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.9048

Authors: Liza Cosca Villaruz, Grace Huang, Marjorie Romkes, John M. Kirkwood, Shama C. Buch, Tomoko Nukui, Keith Flaherty, Sandra J. Lee, Adrian Lee, Kusum Pandit, Irina Abecassis, Katherine L. Nathanson, Panayiotis V Benos, Hussein Abdul-Hassan Tawbi

Institutions: UPMC Hillman Cancer Center, University of Pittsburgh, Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, University of Pennsylvania

Language: English

Topic: MicroRNA in disease regulation

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2592040030

Cites:

Cited by:

Related to: 10